Michael Lowe

36 posts

Michael Lowe

@MichaelCLoweMD

Surgical oncologist, melanoma specialist, researcher, husband, father

Atlanta, GA Katılım Ocak 2018

107 Takip Edilen317 Takipçiler

Michael Lowe@MichaelCLoweMD·24 Oca

@WinshipAtEmory Join us for an incredible group of speakers to discuss updates in management of melanoma, MCC, SCC, and difficult pigmented lesions @DrSapnaPatel @MarkFariesMD @SuephyC Michael Tetzlaff @UCSFCancer Chris Barker @MSKCancerCenter

English

Winship Cancer Institute of Emory University@WinshipAtEmory·9 Oca

The Winship Melanoma and Cutaneous Oncology Conference on March 2 in Atlanta, Georgia, will feature speakers discussing updates on practice-changing data impacting outcomes for patients with #melanoma and other cutaneous malignancies. More info at: brnw.ch/21wFVg7. #melsm

Winship Cancer Institute of Emory University tweet media

English

640

Michael Lowe retweetledi

SWOG Cancer Research Network@SWOG·2 Mar

Results of @SWOG S1801 in @NEJM: Patients w resectable melanoma who got 3 doses of pembrolizumab before surgery & 15 doses after had significantly longer event-free survival than those who got 18 doses after surgery. nejm.org/doi/full/10.10… @DrSapnaPatel @MDAndersonNews @UCLAJCCC

SWOG Cancer Research Network tweet media

English

144

29.1K

Michael Lowe@MichaelCLoweMD·13 Kas

@Chrystal_Paulos @WinshipAtEmory @sitcancer Thanks to @gmboland and @sitcancer for the invitation to highlight with @AshleyHolderMD the importance of surgeons in the care of patients with metastatic melanoma @EmorySurgery

English

Chrystal Paulos@Chrystal_Paulos·12 Kas

Excellent talk by Dr. Mike Lowe ⁦@MichaelCLoweMD⁩ ⁦from ⁦@WinshipAtEmory⁩ ⁦@sitcancer⁩ on the expanding role of surgery in Stage IV Melanoma. #SITC2022!

English

Michael Lowe@MichaelCLoweMD·12 Eyl

Grateful for the tremendous efforts of the study team and our patients (and for the support of great colleagues like @CrisyRoland). What neoadjuvant regimen is the right one?! @WinshipAtEmory

Christina Roland, MD, MS@CrisyRoland

@MichaelCLoweMD @EmorySurgery presenting exciting data evaluating pepinimab +/- nivolumab/ipilimimab in patients with resectable melanoma.

English

Michael Lowe@MichaelCLoweMD·11 Eyl

Congratulations @DrSapnaPatel and the S1801 study team on an incredible practice-changing effort @WinshipAtEmory @MDAndersonNews

English

Michael Lowe@MichaelCLoweMD·9 Tem

@LesinskiLab @WinshipAtEmory @EmoryUniversity Come join our collaborative multidisciplinary and translational team of outstanding melanoma scientists and clinicians @zach_buchwald @Chrystal_Paulos.

English

Gregory Lesinski@LesinskiLab·6 Tem

Calling all awesome medical oncologists!!!! Come join our uniquely collaborative and dynamic team @WinshipAtEmory @EmoryUniversity great opportunities in #GIoncology and #melanoma message me with any questions! nam11.safelinks.protection.outlook.com/?url=https%3A%…

English

Michael Lowe@MichaelCLoweMD·14 Nis

Excited to join my colleagues @TJH0828 @ragikudchadkar and Scott Albert in a thought provoking discussion.

Society of Surgical Oncology@SocSurgOnc

Sign up for a new virtual tumor board on April 25. @TJH0828, Scott Albert, MD, @MichaelCLoweMD & Ragini Kudchadkar, MD, will have a case-based discussion on evidence supporting neoadjuvant systemic therapy for surgically resectable #melanoma. Register at ow.ly/2CCA50IIbrh.

English

Michael Lowe@MichaelCLoweMD·23 Ağu

@SESC_AmSurg Congrats to @RandiSmithMD for her excellent pitch to the sharks. Privileged to moderate with my Research Committee co- chair Jim McLoughlin on behalf of the committee and the @SESC_AmSurg @EmorySurgery

English

Michael Lowe retweetledi

SESC & The American Surgeon@SESC_AmSurg·22 Ağu

SESC Sharks!

English

Michael Lowe retweetledi

Winship Cancer Institute of Emory University@WinshipAtEmory·12 Tem

Emory investigators will receive a total of $955,000 in funding for new research projects from the Morningside Center for Innovative and Affordable Medicine. The six awards include five team projects led by researchers from Winship. ➡️ fal.cn/3gHqf

English

Michael Lowe@MichaelCLoweMD·3 Tem

Proud to represent @emoryhealthcare @WinshipAtEmory and @EmorySurgery throwing out first pitch @Braves tonight.

English

142

Michael Lowe retweetledi

Ragini Kudchadkar, MD@ragikudchadkar·3 Tem

Perfect pitch @MichaelCLoweMD! @Braves @WinshipAtEmory @EmoryHealthcare #SunSafety

English

Michael Lowe retweetledi

Winship Cancer Institute of Emory University@WinshipAtEmory·30 Haz

Winship and the @Braves have partnered to promote #sunsafety this summer. Winship surgical oncologist @MichaelCLoweMD will throw out the first pitch at the Braves game this Friday night and remind fans to play it safe in the sun. #EmoryBraves ⚾ emoryhealthcare.org/sunsafety

English

Michael Lowe retweetledi

Society of Surgical Oncology@SocSurgOnc·5 Haz

In the latest episode of SurgOnc Today, Richard White, MD, moderates as Nasreen Vohra, MD, reviews updates on local therapies and @MichaelCLoweMD reviews updates on neoadjuvant trials in #melanoma. Listen at ow.ly/WV5450F3nv1 or subscribe on Apple Podcasts and Spotify.

Society of Surgical Oncology tweet media

English

Michael Lowe retweetledi

Melanoma and Skin Cancer Trials (MASC Trials)@MASC_Trials·9 Haz

Another significant step forward for MelMarT-II, with 23 more participants recruited last month. A fantastic global effort to improve outcomes for patients with stage II primary #melanoma. More info at masc.org.au/recruiting-tri… #clinicaltrials #surgery #cancerresearch

Melanoma and Skin Cancer Trials (MASC Trials) tweet media

English

Michael Lowe@MichaelCLoweMD·5 Haz

@WinshipAtEmory Great collaboration with @ragikudchadkar

English

Michael Lowe retweetledi

Winship Cancer Institute of Emory University@WinshipAtEmory·4 Haz

#ASCO21 | Poster Session | Melanoma/Skin Cancers "Winship 4851-19: A pilot study of neoadjuvant and adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma" First Author: Michael Lowe, MD, MA (@MichaelCLoweMD) ➡️ fal.cn/3fRzT

English

Michael Lowe retweetledi

Winship Cancer Institute of Emory University@WinshipAtEmory·23 Nis

#WinshipClinicalTrial UCDCCSO034 | Biomarker Analysis of Neoadjuvant Intralesional Therapy in High-Risk Primary #Melanoma: A Multi-Institutional Phase II Study #melsm ➡️ fal.cn/3eVtV

English

Michael Lowe retweetledi

Tina J Hieken MD@TJH0828·15 Nis

Analysis of Head/Neck Melanoma Rx in post-MSLT 2 era from Dr. Baecher @WinshipAtEmory and colleagues from 21 centers #EADO2021 @KristyBroman @MoffittNews @USouthFlorida @tashahughesmd @umichsurgery @leslydossett @jamessunmd @mikejcarr @sloan_kettering @MelanomaAus @OlofssonBagge

English

Michael Lowe@MichaelCLoweMD·12 Nis

Congrats to a great team led by @KristyBroman @jzager99 Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after MSLT‐2 acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

English

Keşfet

@WinshipAtEmory @DrSapnaPatel @MarkFariesMD @SuephyC @UCSFCancer @MSKCancerCenter @SWOG @NEJM